# US 2001/0026932 A1 · CD40-binding APC-activating molecules

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2001/0026932 A1
- Document ID: US20010026932A1
- Status: Published application
- Kind: A1
- Application number: 09/773,866
- Filed: 2001-02-01
- Published: 2001-10-04
- Earliest claimed: 2000-02-01
- Assignees: Pangenetics BV
- Inventors: David Thomas; Mark De Boer; Pieter C.J.M. Res; Peter J. Simons
- Web page: https://patentgrep.com/patent/US20010026932A1

## CPC

- A61K 39/39541: {against normal tissues, cells}
- A61P 35/00: Antineoplastic agents
- A61P 37/02: Immunomodulators
- C07K 16/2818: {against CD28 or CD152}
- C07K 16/2878: {against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 2039/505: {comprising antibodies}
- C07K 2317/31: multispecific
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Disclosed are agonist anti-CD40 molecules, including monoclonal antibodies, which can bind to and stimulate professional and non-professional human antigen-presenting cells (“APCs”), enhance the stimulatory effect of CD40L on CD40 positive cells and/or induce phenotypical maturation of monocyte derived dendritic cells. Several such monoclonal antibodies are provided, and cell lines producing them have been deposited at the American Type Culture Collection.

## Claims

### Claim 1

Agonist anti-CD40 molecules that can bind to and stimulate professional or non-professional human APCs.

### Claim 2 (depends on 1)

The agonist anti-CD40 molecules of claim 1 wherein the human professional APCs are human dendritic cells

### Claim 3

Agonist anti-CD40 molecules which enhance the stimulatory effect of CD40L on CD40 positive cells.

### Claim 4

Agonistic anti-CD40 molecules which induce phenotypical and functional maturation of monocyte derived dendritic cells.

### Claim 5 (depends on 1, 2, 3, 4)

The agonist anti-CD40 molecules of claim 1, 2, 3 or 4 wherein said molecules can simultaneously bind to CD40 with CD40L, as determined by their inability to inhibit CD40L binding to CD40 or their inability to inhibit of binding of sCD40 to CD40L.

### Claim 6 (depends on 1, 2, 3, 4)

The agonist anti-CD40 molecules of claim 1, 2, 3 or 4 which completely inhibit CD40L binding to CD40.

### Claim 7 (depends on 1, 2, 3, 4, 5)

A composition comprising a combination of agonist anti-CD40 molecules according to any of claims 1 to 5.

### Claim 8 (depends on 7)

The composition of claim 7 including at least one agonist anti-CD40 molecule which is a strong activator of binding of sCD40L to CD40, and at least one agonist anti-CD40 molecule which is a partial or non-inhibitor of binding of sCD40L to CD40 and of binding of sCD40 to CD40L.

### Claim 9 (depends on 1, 2, 3, 4, 5, 6)

The agonist anti-CD40 molecules of any of claims 1 to 6 which are monoclonal antibodies.

### Claim 10

A bispecific agonist anti-CD40 monoclonal antibody wherein each specificity is for a different epitope on CD40.

### Claim 11 (depends on 10)

The bispecific monoclonal antibody of claim 10 wherein one specificity is a strong activator of binding of sCD40L to CD40, and one specificity is a partial or non-inhibitor of binding of sCD40L to CD40.

### Claim 12 (depends on 9)

The monoclonal antibodies of claim 9 which are chimeric, humanized, Deimmunised™ or human.

### Claim 13 (depends on 12)

The monoclonal antibodies of claim 12 or fragments, analogues or homologues thereof, or a peptide, oligonucleotide, peptidomimetic or an organic compound which binds to the same epitopes as such antibodies.

### Claim 14 (depends on 13)

The fragments of claim 13 which are Fab, F(ab′)2 Fv or single chain Fv.

### Claim 15 (depends on 9)

Cell lines producing the monoclonal antibodies or fragment thereof of claim 9.

### Claim 16 (depends on 12)

Cell lines producing the monoclonal antibodies or fragment thereof of claim 12.

### Claim 17 (depends on 12)

Gene constructs coding for any of the molecules of claim 12.

### Claim 18 (depends on 13)

Gene constructs coding for any of the molecules of claim 13.

### Claim 19 (depends on 17)

Cells transfected or infected with the gene constructs of claim 17.

### Claim 20 (depends on 18)

Cells transfected or infected with the gene constructs of claim 18.
